EP0399732A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Benzimidazole derivatives
Assignee: Syngenta Ltd
•
Filing: 1990-05-18
•
Granted: —
•
Expires: 2010-05-18
Abstract
Abstract The invention concerns heterocyclic compounds of the formula I (and their physiologically acceptable salts), together with pharmaceutical compositions containing them. The heterocyclic compounds antagonise the actions of angiotensin II and are of value in treating diseases or medical conditions such as hypertension and congestive heart failure in warm-blooded animals. The invention further includes processes for the manufacture of the compounds and their use in medical treatment.
Inventors
- 👤 David Anthony Roberts
- 👤 Simon Thomas Russell
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 15:22
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/10; A; A61; A61P; A61P9/00; A61P9/12; C07D235/00; C07D235/02; C07D235/04; C07D235/06; C07D235/08
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
506 words
A process for the manufacture of a benzimidazole derivative of the formula I wherein R¹ is (1-8C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-4C)alkyl, phenyl or phenyl(1-4C)alkyl; R² is hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano or nitro; R³ and R⁴ are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano and nitro; X is phenylene optionally bearing a substituent selected from (1-4C)alkyl, (1-4C)alkoxy and halogeno, or X is a direct bond between the adjacent phenyl and methylene moieties; and Z is 1 H -tetrazol-5-yl or a group of the formula -CO.OR⁵ or -CO.NH.SO₂.R⁶ in which R⁵ is hydrogen or a non-toxic, biodegradable residue of a physiologically acceptable alcohol or phenol, and R6 is (1-6C)alkyl, (3-8C)cycloalkyl or phenyl; and wherein any of said phenyl moieties may be unsubstituted or bear one or two substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy, halogeno, cyano and trifluoromethyl; or a physiologically acceptable salt thereof except when R5 is other than hydrogen; which is characterised in that:- (a) for those compounds in which Z is carboxy, a carboxylic derivative of the formula II in which Q is a protected carboxy group selected from (1-6C)alkoxycarbonyl, phenoxycarbonyl, benzyloxycarbonyl and carbamoyl, is converted to carboxy; (b) for those compounds of formula I wherein Z is tetrazolyl, a compound of the formula III in which L is a suitable protecting group affixed to a nitrogen of the tetrazolyl moiety, is deprotected; (c) for those compounds of formula I wherein Z is a group of the formula -CO.OR⁵, a benzimidazole of the formula IV is reacted with a compound of the formula V wherein Hal. stands for a suitable leaving group; or (d) a 1,2-diamino derivative of the formula VII is reacted with a carboxylic acid of the formula R¹.CO₂H or a (1-4C)alkyl orthoester thereof; whereafter, when a compound of the formula I is required wherein Z is a group of the formula -CO.NH.SO₂R⁶ or a group of the formula -CO.OR⁵ in which R⁵ is other than hydrogen, a carboxylic acid of the formula I in which Z is carboxy (or a reactive derivative of said acid) is reacted with a sulphonamide of the formula NH₂.SO₂R⁶ or a hydroxy compound of the formula HO.R⁵ , or with a salt thereof; whereafter, when a salt of a compound of formula I is required, it is obtained by reaction with the appropriate base affording a physiologically acceptable ion, or by any other conventional salt formation procedure; and when an optically active form of a compound of formula I is required, one of the processes (a)-(d) is carried out using an optically active starting material, or the racemic form of a compound of formula I in which Z is an acidic group is resolved by reaction with an optically active form of a suitable organic base, followed by conventional separation of the diastereoisomeric mixture of salts thus obtained, and liberation of the required optically active form of said compound of formula I by conventional treatment with acid; and wherein R¹, R², R³, R⁴, X and Z have any of the meanings defined above unless otherwise stated.
Claim 2
Dependent Claim
506 words
A process for the manufacture of a benzimidazole derivative of the formula I wherein R¹ is (1-8C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-4C)alkyl, phenyl or phenyl(1-4C)alkyl; R² is hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano or nitro; R³ and R⁴ are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy, halogeno, trifluoromethyl, cyano and nitro; X is phenylene optionally bearing a substituent selected from (1-4C)alkyl, (1-4C)alkoxy and halogeno, or X is a direct bond between the adjacent phenyl and methylene moieties; and Z is 1 H -tetrazol-5-yl or a group of the formula -CO.OR⁵ or -CO.NH.SO₂.R⁶ in which R⁵ is hydrogen or a non-toxic, biodegradable residue of a physiologically acceptable alcohol or phenol, and R6 is (1-6C)alkyl, (3-8C)cycloalkyl or phenyl; and wherein any of said phenyl moieties may be unsubstituted or bear one or two substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy, halogeno, cyano and trifluoromethyl; or a physiologically acceptable salt thereof except when R5 is other than hydrogen; which is characterised in that:- (a) for those compounds in which Z is carboxy, a carboxylic derivative of the formula II in which Q is a protected carboxy group selected from (1-6C)alkoxycarbonyl, phenoxycarbonyl, benzyloxycarbonyl and carbamoyl, is converted to carboxy; (b) for those compounds of formula I wherein Z is tetrazolyl, a compound of the formula III in which L is a suitable protecting group affixed to a nitrogen of the tetrazolyl moiety, is deprotected; (c) for those compounds of formula I wherein Z is a group of the formula -CO.OR⁵, a benzimidazole of the formula IV is reacted with a compound of the formula V wherein Hal. stands for a suitable leaving group; or (d) a 1,2-diamino derivative of the formula VII is reacted with a carboxylic acid of the formula R¹.CO₂H or a (1-4C)alkyl orthoester thereof; whereafter, when a compound of the formula I is required wherein Z is a group of the formula -CO.NH.SO₂R⁶ or a group of the formula -CO.OR⁵ in which R⁵ is other than hydrogen, a carboxylic acid of the formula I in which Z is carboxy (or a reactive derivative of said acid) is reacted with a sulphonamide of the formula NH₂.SO₂R⁶ or a hydroxy compound of the formula HO.R⁵ , or with a salt thereof; whereafter, when a salt of a compound of formula I is required, it is obtained by reaction with the appropriate base affording a physiologically acceptable ion, or by any other conventional salt formation procedure; and when an optically active form of a compound of formula I is required, one of the processes (a)-(d) is carried out using an optically active starting material, or the racemic form of a compound of formula I in which Z is an acidic group is resolved by reaction with an optically active form of a suitable organic base, followed by conventional separation of the diastereoisomeric mixture of salts thus obtained, and liberation of the required optically active form of said compound of formula I by conventional treatment with acid; and wherein R¹, R², R³, R⁴, X and Z have any of the meanings defined above unless otherwise stated.
Claim 3
Dependent Claim
156 words
A process according to claim 1 wherein in the starting materials R¹ is methyl, ethyl, propyl, butyl, isobutyl, sec -butyl, pentyl, hexyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopentyl-ethyl, phenyl, benzyl, 1-phenylethyl or 2-phenylethyl; R² is hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, iodo, trifluoromethyl, cyano or nitro; R³ and R⁴ are independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, iodo, trifluoromethyl, cyano and nitro; X is phenylene optionally bearing a substituent selected from methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo and iodo, or X is a direct bond between the adjacent phenyl and methylene moieties; R⁵ is hydrogen or a residue derived from a (1-6C)alkanol, phenol or glycerol; and R⁶ is methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl; and wherein any of said phenyl moieties may be unsubstituted or bear one or two substituents independently selected from methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, cyano and trifluoromethyl.
Claim 4
Dependent Claim
21 words
The use of a compound of the formula I as defined in claim 1 in the manufacture of a novel medicament.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.